A Meta-Analysis of Cognitive Impairment and Decline Associated with Adjuvant Chemotherapy in Women with Breast Cancer

Ono, Miyuki; Ogilvie, James; Wilson, J.; Green, Heather; Chambers, Suzanne K.; Ownsworth, Tamara; Shum, David

doi:10.3389/fonc.2015.00059

Cited by 121 publications

(118 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While CTX is associated with decreases in cognitive function, 44,61,69 the relationship between pain and cognitive function has not been evaluated in patients on CTX. AFI scores for patients in our study were slightly lower than scores of patients at the initiation of RT 60 or prior to breast cancer surgery.…”

Section: Discussionmentioning

confidence: 99%

Differences in demographic, clinical, and symptom characteristics and quality of life outcomes among oncology patients with different types of pain

Posternak¹,

Dunn

Dhruva

et al. 2016

Pain

View full text Add to dashboard Cite

The purposes of this study, in oncology outpatients receiving chemotherapy (CTX, n=926), were to: describe the occurrence of different types of pain (i.e., no pain, only non-cancer pain (NCP), only cancer pain (CP), or both CP and NCP) and evaluate for differences in demographic, clinical, and symptom characteristics, and quality of life (QOL) among the four groups. Patients completed self-report questionnaires on demographic and symptom characteristics and QOL. Patients who had pain were asked to indicate if it was or was not related to their cancer or its treatment. Medical records were reviewed for information on cancer and its treatments. In this study, 72.5% of the patients reported pain. Of the 671 who reported pain, 21.5% reported only NCP, 37.0% only CP, and 41.5% both CP and NCP. Across the three pain groups, worst pain scores were in the moderate to severe range. Compared to the no pain group, patients with both CP and NCP were significantly younger, more likely to be female, have a higher level of comorbidity and a poorer functional status. In addition, these patients reported: higher levels of depression, anxiety, fatigue, and sleep disturbance; lower levels of energy and attentional function; and poorer QOL. Patients with only NCP were significantly older than the other three groups. The most common comorbidities in the NCP group were back pain, hypertension, osteoarthritis, and depression. Unrelieved CP and NCP continue to be significant problems. Oncology outpatients need to be assessed for both CP and NCP conditions.

show abstract

Section: Discussionmentioning

confidence: 99%

Differences in demographic, clinical, and symptom characteristics and quality of life outcomes among oncology patients with different types of pain

Posternak¹,

Dunn

Dhruva

et al. 2016

Pain

View full text Add to dashboard Cite

show abstract

“…A comprehensive assessment of spatial cognitive ability was not performed in previous studies. In addition, confounders such as chemotherapy were excluded, even if the magnitude of the impact of chemotherapy is still controversial [17,37]. In a meta-analysis of 17 studies on chemotherapy-induced cognitive impairment in patients with breast cancer, Jim et al [38] reported an impairment of verbal and visuospatial ability compared to healthy controls.…”

Section: Discussionmentioning

confidence: 99%

“…This involves the risk that potential differences remain undetected. Generally, a differentiation between patients receiving chemotherapy and endocrine therapy is essential, because chemotherapy is a potential confounder [37,38]. Different types of endocrine therapy - anti-estrogens and AIs - should be studied separately.…”

Section: Discussionmentioning

confidence: 99%

Memory and Spatial Cognition in Breast Cancer Patients Undergoing Adjuvant Endocrine Therapy

et al. 2016

View full text Add to dashboard Cite

Introduction: It is generally accepted that estrogens play a protective role in cognitive function. Therefore, it can be expected that subtotal estrogen deprivation following aromatase inhibition will alter cognitive performance. Methods: In a cross-sectional study we investigated 80 postmenopausal women with breast cancer. Memory and spatial cognition were compared across 4 treatment groups: tamoxifen only (TAM, n = 22), aromatase inhibitor only (AI, n = 22), TAM followed by AI (‘SWITCH group', n = 15), and patients with local therapy (LT) only (surgery and radiation, n = 21). Duration of the 2 endocrine monotherapy arms prior to the assessment ranged from 1 to 3 years. The ‘SWITCH group' received 2-3 years TAM followed by at least 1 year and at most 3 years of AI. Memory and spatial cognition were investigated as planned comparisons. Investigations of processing speed, attention, executive function, visuoconstruction and self-perception of memory were exploratory. Results: With regard to general memory, AI patients performed significantly worse than the LT group (p = 0.013). Significant differences in verbal memory did not remain significant after p-value correction for multiple testing. We found no significant differences concerning spatial cognition between the groups. Conclusion: AI treatment alone significantly impairs general memory compared to the LT group.

show abstract

“…Dowodzą temu liczne metaanalizy opierające się na wynikach badań tej grupy pacjentek [17][18][19][20][21].…”

Section: Chemobrain a Szpiczak Mnogiunclassified

Review paper. Chemobrain in patients suffering from cancer based on the example of multiple myeloma

Bury

2017

Current Problems of Psychiatry

View full text Add to dashboard Cite

Introduction: The incidence rate of cancers emphasizes the necessity to investigate not only patients' somatic ailments but also their psychosocial functioning as well as the need to raise the quality standards of cancer patients. The improvement of the quality of life is one of the major challenges of psycho-oncology, which is the science created in the interface of two disciplines: psychology and medicine.One of the important aspects of psycho-oncologists' activity is the minimization of negative side-effects related to treatment, such as changes in patients' cognitive functioning resulting from anti-cancer treatment.Objective: The aim of this work is to provide the reader with the knowledge concerning the phenomenon of chemobrain in a very special group of patients with hemato-oncologic tumour. Few researches related to this topic have confirmed the occurrence of cognitive deficits resulting from the cancer process, taken cytotoxic drugs, other forms of anti-cancer therapy and the activeness of biochemical compounds in patients with multiple myeloma.Methods: The author has done a literary review concerning the topic under study using the Google Scholar and EBSCO databases. The main part of this work consists of references to Polish and English research literature published after 2000. The review includes also classic works from the eighties and nineties of the 20th century.Results: The present work has been divided into several sections. The part devoted to explanation of the term chemobrain describes the evolution of its definition over the years. The second section -'Heterogeneity of the phenomenon -causes' -underlines the influence of biochemical etiological factors, such as the impact of the activity of proinflammatory cytokines on the cognitive state of the patients suffering from tumour. Next part -'Chemobrain and multiple myeloma' is devoted to the clinical characteristics of this cancer and to the descriptions of the selected methods of chemotherapy. The review of researches concerning the deteriorated cognitive functioning of patients with multiple myeloma in relation to the probable aetiology of this disease has been also presented.Conclusions: The review of Polish and English literature concerning the functioning of memory and attention processes in the patients suffering from multiple myeloma can serve as an inspiration for a search for objective biochemical factors conditioning the deterioration of cognitive processes of the patients undergoing anti-cancer treatment.

show abstract

A Meta-Analysis of Cognitive Impairment and Decline Associated with Adjuvant Chemotherapy in Women with Breast Cancer

Cited by 121 publications

References 48 publications

Differences in demographic, clinical, and symptom characteristics and quality of life outcomes among oncology patients with different types of pain

Differences in demographic, clinical, and symptom characteristics and quality of life outcomes among oncology patients with different types of pain

Memory and Spatial Cognition in Breast Cancer Patients Undergoing Adjuvant Endocrine Therapy

Review paper. Chemobrain in patients suffering from cancer based on the example of multiple myeloma

Contact Info

Product

Resources

About